TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment of Refractory or Recurrent AML
Source: Acute Myeloid Leukemia Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
No standard treatment regimen exists for patients with refractory or recurrent acute myeloid leukemia (AML).[1,2]
Treatment options for refractory or recurrent AML include:
Chemotherapy.
Source links and citations
Chemotherapy.
Intensive salvage chemotherapy.
Source links and citations
Chemotherapy.
Reduced-intensity therapy, including targeted therapy.
Source links and citations
Allogeneic hematopoietic cell transplant (HCT).
Source links and citations
Continue within this section
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice